Re: Directorate Change

RNS Number : 5491S
Cambridge Cognition Holdings PLC
08 July 2015
 

8 July 2015

 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Re: Directorate Change

 

Further to the Company's announcement of 1 July 2015, the following information regarding the appointment of Steven John Powell, aged 53, is disclosed pursuant to paragraph (g) of Schedule Two to the AIM Rules for Companies.

 

Other directorships and partnerships held:

 

Current

Within the last 5 years

CE Bioscience Limited

Andron Pharma Limited

Chroma Therapeutics Limited

Fast Track Pharma (Holdings) Limited

Fast Track Pharma Limited

Plethora Solutions Holdings PLC

Macrotarg Limited

Plethora Solutions Limited

The Brain Tumour Charity

Plethora Therapeutics Limited

The Native Antigen Company Limited

The Urology Company Holdings Limited

The Truffaldino Partnership Limited

The Urology Company Limited

 

 

There is no further information on Dr. Powell required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Michael Lewis, Chairman

Steven Powell, Chief Operating Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer




finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)



Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUWSVRVNABRAR
UK 100

Latest directors dealings